Yet, limitations in the experimental studies, as mentioned above, and the absence of clinical investigations hinder a conclusive determination of the beneficial role of IL-22 in the context of MASH. This evidence concerns the gene IL22 and metabolic dysfunction-associated steatohepatitis.